SCHEMBL14630769

SCHEMBL14630769

O=C(O)[C@H]1[C@@H]2COC[C@@H]21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135804 1.00
SCHEMBL5135807 1.00
SCHEMBL5135805 1.00
SCHEMBL1584181 1.00
SCHEMBL14630771 1.00
SCHEMBL1583972 1.00
SCHEMBL1583863 1.00
SCHEMBL2685140 1.00
SCHEMBL19206038 0.89 KDM4E (0.39)
SCHEMBL17528518 0.89 KDM4E (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078133-A1 RAS INHIBITORS Revolution Medicines, Inc. 2026-03-19 US disclosed
EP-4653438-A1 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2025-11-26 EP disclosed
EP-4584259-A1 CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS Innovo Therapeutics, Inc. (US) 2025-07-16 EP disclosed
WO-2025051241-A1 MACROCYCLIC COMPOUND AND ANTIBODY-DRUG CONJUGATE THEREOF 劲方医药科技(上海)股份有限公司 2025-03-13 WO disclosed
WO-2024153208-A9 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF 劲方医药科技(上海)有限公司 2024-08-22 WO disclosed
WO-2024153208-A1 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF 劲方医药科技(上海)有限公司 2024-07-25 WO disclosed
US-20240158370-A1 CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. 2024-05-16 US disclosed
WO-2024054832-A1 CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. (US) 2024-03-14 WO disclosed
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-06-29 US disclosed
EP-3589618-B1 PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2022-12-28 EP disclosed
US-20170008891-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. 2017-01-12 US disclosed
US-20170008899-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-01-12 US disclosed
US-20160002228-A1 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS GENENTECH, INC. (US) 2016-01-07 US disclosed
US-20160002228-A1 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS GENENTECH, INC. (US) 2016-01-07 US disclosed
US-20160002228-A1 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS GENENTECH, INC. (US) 2016-01-07 US disclosed
US-20150299197-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. 2015-10-22 US disclosed
US-20140275082-A1 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. 2014-09-18 US disclosed
US-20140221333-A1 BTK INHIBITORS MERCK SHARP & DOHME B.V. (NL) 2014-08-07 US disclosed
WO-2014111496-A1 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-24 WO disclosed
EP-2548877-A1 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors MSD Oss B.V. (NL) 2013-01-23 EP disclosed